Anti-IL-17A (Taltz) (Ixekizumab biosimilar) mAb, IgG4, Human Humanized, Monoclonal

Produktübersicht

• Artikelname: Anti-IL-17A (Taltz) (Ixekizumab biosimilar) mAb, IgG4, Human Humanized, Monoclonal
• Artikelnummer: ABI-12-2002
• Hersteller Artikelnummer: 12-2002
• Alternativnummer: ABI-12-2002-100UG
• Hersteller: Abeomics
• Wirt: Human Humanized
• Kategorie: Antikörper
• Applikation: ELISA
• Spezies Reaktivität: Human

Produktbeschreibung

Ixekizumab/ Anti-IL-17A (Taltz) is a humanized IgG4 biosimilar monoclonal antibody expressed by mammalian cell lines that block the biological activity of IL-17A. IL-17A is a pro-inflammatory cytokine that triggers immune cells like neutrophils, lymphocytes, macrophages, monocytes, natural killer (NK) cells, and B cells that play essential roles in innate and adaptive immune responses. IL-17A binds IL17RA-IL17RC heterodimeric receptor complex to activate TRAF6 and NF-kappaB pathway, leading to pro inflammatory cytokines and chemokines gene expression. The Ixekizumab biosimilar developed by Abeomics is a high-quality research grade biosimilar and is not to be used for therapeutic or diagnostic procedures for humans and animals.

Produkteigenschaften

• Klonalität: Monoclonal
• Isotyp: IgG4
• Reinheit: Purified from cell culture supernatant by affinity chromatography

Anwendungsbeschreibung

• Application Verdünnung: ELISA 1:5000-10000, FACS 1:100